Irish pharma firm Amryt nears approval for butterfly skin treatment
EMA has 67 days to decide whether to back recommendation of its expert committee
Amryt announces plan to delist from AIM in London
Drug firm says says delisting would enhance liquidity of trading
Irish pharma group Amryt reports 15% revenue growth for third quarter
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
Record sales for Irish rare disease specialist Amryt
Company upgrades forecasts as it completes Chiasma takeover
Amryt Pharma granted priority review of ‘butterfly skin’ treatment
US Food and Drug Administration’s priority review can expedite review process to six months
Dublin-based Amryt buys US firm Chiasma in deal worth $330m
Drug group expands its portfolio of medicines while reporting first-quarter numbers
Amryt progresses with bid to win US approval for ‘butterfly skin’ treatment
Rolling submission began last summer
Biopharma group Amryt reports 19% jump in revenue in third quarter
Results are a record for Dublin-based company, which has recently listed on Nasdaq
Amryt signs agreement to distribute Lojuxta
Swixx BioPharma will sell cholesterol drug across central and eastern Europe
Amryt shares surge on success in drug trial for ‘butterfly skin’
Irish specialist in rare diseases says successful drug could tap $1bn market
EY Entrepreneur of the Year international finalists focusing on growth
Sectors include health and safety, pharma, crop protection and refrigeration
Irish pharma company Amryt almost doubles CEO pay to $1.6m
Chief executive Joe Wiley also received more than 6m share options in company
Biopharma group Amryt reports 30% jump in revenue
Rare disease specialist says integration with newly acquired Aegerion completed ahead of time
Amryt Pharma recorded 13.1% rise in revenue last year
Company said the impact of Covid-19 on its business has been minimised so far
Amryt says integration of acquired company Aegerion ‘progressing well’
Dublin-based biopharma company has cash position of $60.9m
Dublin pharma company Amryt grows sales almost 20%
Firm acquired US-based Aegerion Pharmaceuticals earlier this year
Amryt acquires company with plans to grow portfolio
Group plots dual Nasdaq listing to create enlarged rare disease company
Amryt gets 2019 off to strong start following 13% revenue rise in 2018
Lojuxta revenues driven by UK, France reimbursement approval
Carrick Therapeutics head Sullivan named best emerging entrepreneur
Elaine Sullivan leads cancer research firm to an EY Entrepreneur of the Year Award
Sales of Amryt Pharma cholesterol drug up 14.6%
Amyrt’s EB development asset progressing through phase three clinical trial
Amryt skin therapy trial gets green light in US
Approval for treatment for rare genetic condition paves way for clinical trials in US
Amryt Pharma wins key US drug designation
FDA move means Irish company could receive voucher ultimately worth up to €300m
Amryt Pharma heart drug wins approval from NHS England
Drug treats rare condition which can lead to early blocking of arteries and heart attacks
Dublin entrepreneur targeting treatments for rare diseases
EY Entrepreneur of the Year finalist Dr Joe Wiley of Amryt Pharma
Amryt signs new deal to expand Lojuxta licence
Firms estimates new deal will increase number of patients for treatment by 25%
EY Entrepreneur of the Year: 24 companies shortlisted for award
Finalists employ more than 2,700 people and generate annual revenues of €150m
Amryt reports strong 2017 as revenues rise to almost €13m
Biopharma firm signs new deal for gene therapy that could treat genetic condition EB
Amryt Pharma signs distribution agreement in middle east
Company has further expanded its market coverage for Lojuxta
Amryt signs new distribution deal for Lojuxta
Latest deal is fourth in three months for Ierish biopharmaceutical company
Amryt Pharma appoints new head of regulatory affairs
Derval O’Carroll has more than 25 years experience in pharmaceutical industry
Amryt Pharma signs deal for drug distribution in Switzerland
Lojuxta deal is ‘key step’ in growing company’s business for drug in EMEA region
Amryt Pharma to raise €15m to treat rare skin disorder
Placing is conditional on shareholder approval at a general meeting on October 9th
Sales jump at rare disease drug group Amryt Pharma
Company starts phase III trial for ‘butterfly skin’ disease
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices